Geron (NASDAQ:GERN) Stock Price Down 3.5%

Geron Co. (NASDAQ:GERN) shares traded down 3.5% during trading on Wednesday . The stock traded as low as $4.35 and last traded at $4.36. 1,247,197 shares changed hands during trading, a decline of 89% from the average session volume of 11,632,511 shares. The stock had previously closed at $4.52.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on GERN shares. Barclays assumed coverage on shares of Geron in a research note on Monday, June 10th. They issued an “overweight” rating and a $9.00 price target on the stock. Wedbush reissued an “outperform” rating and set a $7.00 price target on shares of Geron in a research report on Friday, June 7th. The Goldman Sachs Group raised their price target on Geron from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Stifel Nicolaus increased their price objective on Geron from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, June 10th. Finally, Robert W. Baird cut shares of Geron from an “outperform” rating to a “neutral” rating and set a $4.50 target price for the company. in a research note on Tuesday, April 30th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Geron has a consensus rating of “Moderate Buy” and a consensus price target of $6.93.

Geron Trading Down 0.2 %

The business has a fifty day moving average of $4.03 and a two-hundred day moving average of $2.97. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.67 and a current ratio of 3.67.

Geron (NASDAQ:GERN) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. The firm had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.15 million. Geron had a negative net margin of 38,730.00% and a negative return on equity of 68.16%. Equities analysts forecast that Geron Co. will post -0.35 EPS for the current year.

Insider Buying and Selling at Geron

In other news, EVP Faye Feller sold 287,900 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $4.63, for a total transaction of $1,332,977.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Geron news, CEO John A. Scarlett sold 600,000 shares of the business’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $4.00, for a total value of $2,400,000.00. Following the completion of the sale, the chief executive officer now owns 600,000 shares of the company’s stock, valued at approximately $2,400,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Faye Feller sold 287,900 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $4.63, for a total transaction of $1,332,977.00. The disclosure for this sale can be found here. Insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Geron

Large investors have recently added to or reduced their stakes in the stock. Federated Hermes Inc. bought a new stake in shares of Geron during the 3rd quarter valued at $29,000. Crewe Advisors LLC grew its stake in Geron by 870.0% during the first quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 8,700 shares in the last quarter. Kingsview Wealth Management LLC acquired a new stake in Geron during the first quarter worth about $34,000. American Trust bought a new position in Geron in the 1st quarter valued at about $38,000. Finally, Twin Peaks Wealth Advisors LLC acquired a new position in shares of Geron in the 4th quarter valued at approximately $58,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.